Kidney disease in African Americans.
Before I get to the tsetse fly, let me briefly review the relationship between sickle hemoglobin and malaria, which is often used to explain heterozygous advantage. The observations underlying this example were made in the first half of the 20th century. In review, a point mutation in the HBB (beta hemoglobin) gene occurred in an individual in Western Africa and then - over centuries, and under the selective presstire of Plasmodium falciparum--the carrier state for this human genetic variant reached high levels. The human population's advantage is that carriers are resistant to malaria; the human population's cost is that sickle cell disease occurs in individuals who harbor two copies of the altered gene. In this scenario, there is a homozygous disadvantage (that is, sickle cell anemia) for people who carry two copies of the altered gene, a homozygous disadvantage (susceptibility to malaria) for people who carry two copies of the unaltered gene, and a heterozygous advantage (resistance to malaria) for people who carry one copy of each.
In August 2010, Glulio Genovese, Ph.D., of Beth Israel Deaconess Medical Center and Harvard Medical School,
Boston, and his colleagues published an article entitled 'Association of Trympa-nolytic APOH Variants with Kidney Disease in African Americans" (Science 2010:329:841-5). While 1 admit the title may not have grabbed the attention of the average clinician in practice, the story is truly amazing. APOLl is one of the human genes for an apolipoprotein, in this case one of the proteins on the surface of HDL cholesterol. It turns out that the parasite that causes African sleeping sickness (Trypanosoma brucei) is destroyed by lysis in the bloodstream of individuals with certain versions of this gene. Specifically, the variants of the APOLl gene designated as the Gl and G2 alleles are associated with resistance to this fatal disease.
The APOLl-renal disease story appears to play out a bit like the HBB-sickle cell disease story. Like the mosquito, the tsetse fly is the disease vector that transmits disease when it bites humans. There is the homozygous disadvantage of susceptibility to sleeping sickness with the normal version of the APOLl gene, and the heterozygous advantage of resistance to the infection with the genetic variant. And as the work of Dr. Genovese and colleagues suggests, there is the homozygous disadvantage of increased renal disease risk with two copies of the genetic variant.
So where does this research lead? In the years ahead, clinical research that looks at factors such as low-protein diets and intensified blood pressure control in individuals with a genetic predisposition will likely yield answers about ways to modify the genetic risk. We hope such clinical research will lead to practical measures that will help counteract inherited risks for renal disease for many Americans.
Dr. Murray is the clinical chief of genetics at Brigham and Women's Hospital and an instructor at Harvard Medical School, both in Boston.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||GENETIC IN YUR PRACTICE|
|Author:||Murray, Michael F.|
|Publication:||Internal Medicine News|
|Date:||Oct 1, 2011|
|Previous Article:||CVD drugs, lifestyle fix erectile dysfunction.|
|Next Article:||Immune-related genetic loci linked to multiple sclerosis.|